Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
ASCO 2024 – Laura’s crossover conundrum
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
ASCO 2024 – Krazati looks more similar than different to Lumakras
Meanwhile, Lilly gets in on the next-gen KRAS action.
ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
ASCO 2024 – Summit peaks on ivonescimab surprise
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
ASCO 2024 – J&J flies towards a more convenient Rybrevant
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
